Orphan drugs (OD) require considerable expenditures, which causes difficulties in their market access. For several years, the price of these new therapies has often been criticized and considered as too high. However few studies about OD pricing mechanisms are available. The aim of the paper is to highlight the main factors that influence OD pricing in France.
